Double-dose hepatitis B revaccination in nonresponsive HIV-infected adolescents.
There is no consensus regarding a best dosing regimen of hepatitis B virus vaccine (HBVV) for non-responsive HIV-infected individuals. Double-dose of hepatitis B vaccine (DDHBVV) could enhance immunogenicity to HBVV in non-responsive HIV-infected adults. We assessed the immunogenicity of DDHBVV in HIV-infected adolescents who failed to respond to standard HBVV revaccination. HIV-infected adolescents with current CD4 ≥ 200 cells/mm(3) and no protective antibody concentration of hepatitis B surface antibodies (antiHBs) after HBVV revaccination received DDHBVV, at months 0, 1, 2. The HBVV doses were 20 microgram per dose for adolescents aged < 18 years and 40 microgram per dose for adolescents aged ≥ 18 years. AntiHBs titers were measured at 1, 2, 3 months after first DDHBVV. AntiHBs ≥ 10 mIU/ml was considered protective. Seven adolescents were enrolled; mean age was 15.4 years, CD4 was 775 cells/mm(3) and all had HIV-RNA < 50 copies/ml. Proportions of adolescents with protective antiHBs were 86% at months 1 and 2, and 100% at month 3. Geometric means of antiHBs were 1.1 at baseline, 101.6 at 1 month, 137.1 at 2 months, and 355.9 mIU/ml at 3 months after the first DDHBVV. No grade 3-4 adverse event was reported. DDHBVV is an option for HIV-infected adolescents who are non-responder to standard HBVV revaccination.